First Russian recombinant allergy vaccine: a brief review of research results

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Allergen-specific immunotherapy is a form of etiological treatment for patients with immunoglobulin E mediated allergic diseases. Allergen-specific immunotherapy is based on the administration of causative allergens in order to induce immunological tolerance to it. The main advantages of allergen-specific immunotherapy over all other available treatments for allergy are that it induces long-lasting protection and prevents the progression of the disease to more severe manifestations.

This article reviews the results of studies on a promising allergy vaccine developed for allergen-specific immunotherapy in birch pollen allergy.

About the authors

Nataliya I. Ilina

State Research Center — National Medical Research Center for Allergology and Immunology

Email: instimmun@yandex.ru
ORCID iD: 0000-0002-3556-969X
SPIN-code: 6715-5650

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

Olga G. Elisyutina

State Research Center — National Medical Research Center for Allergology and Immunology; RUDN University

Author for correspondence.
Email: el-olga@yandex.ru
ORCID iD: 0000-0002-4609-2591
SPIN-code: 9567-1894

MD, Dr. Sci. (Medicine), Associate Professor

Russian Federation, Moscow; Moscow

Evgeniya V. Nazarova

State Research Center — National Medical Research Center for Allergology and Immunology

Email: evallergo@yandex.ru
ORCID iD: 0000-0003-0380-6205
SPIN-code: 4788-7407

MD, Dr. Sci. (Medicine)

Russian Federation, Moscow

Elena S. Fedenko

State Research Center — National Medical Research Center for Allergology and Immunology

Email: efedks@gmail.com
ORCID iD: 0000-0003-3358-5087
SPIN-code: 5012-7242

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

Oksana M. Kurbacheva

State Research Center — National Medical Research Center for Allergology and Immunology

Email: kurbacheva@gmail.com
ORCID iD: 0000-0003-3250-0694
SPIN-code: 5698-6436

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

Elena A. Latysheva

State Research Center — National Medical Research Center for Allergology and Immunology

Email: ealat@mail.ru
ORCID iD: 0000-0002-1606-205X
SPIN-code: 2063-7973

MD, Dr. Sci. (Medicine)

Russian Federation, Moscow

Tatiana V. Latysheva

State Research Center — National Medical Research Center for Allergology and Immunology

Email: tvlat@mail.ru
ORCID iD: 0000-0003-1508-0640
SPIN-code: 8929-7644

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

Andrey E. Shulzhenko

State Research Center — National Medical Research Center for Allergology and Immunology

Email: shulzhenko_ae@mail.ru
ORCID iD: 0000-0003-0268-9350
SPIN-code: 4584-4915

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

Natalia V. Shartanova

State Research Center — National Medical Research Center for Allergology and Immunology

Email: nshartanova@yandex.ru
ORCID iD: 0000-0002-1197-9002
SPIN-code: 6483-8901

MD, Dr. Sci. (Medicine)

Russian Federation, Moscow

Valeriy V. Smirnov

State Research Center — National Medical Research Center for Allergology and Immunology; I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: vall@mail.mipt.ru
ORCID iD: 0000-0002-8232-6682
SPIN-code: 4171-3871

Dr. Sci. (Pharmacy), Professor

Russian Federation, Moscow; Moscow

Igor P. Shilovskiy

State Research Center — National Medical Research Center for Allergology and Immunology

Email: igorshilovski@gmail.com
ORCID iD: 0000-0001-5343-4230
SPIN-code: 6008-7323

Dr. Sci. (Biology)

Russian Federation, Moscow

Musa R. Khaitov

State Research Center — National Medical Research Center for Allergology and Immunology; RUDN University; N.I. Pirogov Russian National Research Medical University

Email: mr.khaitov@nrcii.ru
ORCID iD: 0000-0003-4961-9640
SPIN-code: 3199-9803

MD, Dr. Sci. (Medicine), Professor, Academician of the Russian Academy of Sciences

Russian Federation, Moscow; Moscow; Moscow

References

  1. Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50. doi: 10.1038/nrd4624
  2. Bagnasco D, Ferrando M, Varricchi G, et al. A Critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma. Int Arch Allergy Immunol. 2016;170(2):122–131. doi: 10.1159/000447692
  3. Incorvaia C, Gritti BL, Ridolo E. The economic advantage of allergen immunotherapy over drug treatment in respiratory allergy. J Med Econ. 2018;21(6):553–555. doi: 10.1080/13696998.2018.1423567
  4. Curin M, Khaitov M, Karaulov A, et al. Next-generation of allergen-specific immunotherapies: molecular approaches. Curr Allergy Asthma Rep. 2018;18(7):39. doi: 10.1007/s11882-018-0790-x EDN: YBPQOL
  5. Brüggenjürgen B, Reinhold T. Cost-effectiveness of grass pollen subcutaneous immunotherapy (SCIT) compared to sublingual immunotherapy (SLIT) and symptomatic treatment in Austria, Spain, and Switzerland. J Med Econ. 2018;21(4):374–381. doi: 10.1080/13696998.2017.1419959
  6. Movérare R, Elfman L, Vesterinen E, et al. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy. 2002;57(5):423–430. doi: 10.1034/j.1398-9995.2002.13248.x
  7. Weber M, Niespodziana K, Linhart B, et al. Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines. J Allergy Clin Immunol. 2017;140(5):1433–1436. doi: 10.1016/j.jaci.2017.03.048
  8. Niederberger V, Marth K, Eckl-Dorna J, et al. Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients. J Allergy Clin Immunol. 2015;136(4):1101–1103.e8. doi: 10.1016/j.jaci.2015.03.034
  9. Zieglmayer P, Focke-Tejkl M, Schmutz R, et al. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine. 2016;11:43–57. doi: 10.1016/j.ebiom.2016.08.022
  10. Litovkina A, Nikonova A, Smolnikov E, et al. Impact of the oral allergic syndrome on basophil activation in birch-pollen sensitized patients. Eur J Immunol. 2019;49(Suppl 3):584.
  11. Khaitov M, Shilovskiy I, Valenta R, et al. Recombinant PreS-fusion protein vaccine for birch pollen and apple allergy. Allergy. 2024;79(4):1001–1017. doi: 10.1111/all.15919 EDN: ZMFTEX
  12. Khaitov MR, Valenta R, Skvortsova VI, et al. Pre-seasonal treatment with recombinant carrier-based birch vaccine improves birch pollen allergy. Allergy. 2026;0:1–20. doi: 10.1111/all.70504 EDN: WRQTNY
  13. Mösges R, Raskopf E, Klimek L, et al. Short-course subcutaneous treatment with birch pollen allergoids greatly improves symptom and medication scores in birch allergy. Allergy. 2025;80(3):817–826. doi: 10.1111/all.16387 EDN: EUVRBN
  14. Pfaar O, Bachert C, Kuna P, et al. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma. J Allergy Clin Immunol. 2019;143(3):970–977. doi: 10.1016/j.jaci.2018.11.018 EDN: KGIUCQ
  15. Worm M, Rak S, de Blay F, et al. Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study. Clin Transl Allergy. 2014;4(1):7. doi: 10.1186/2045-7022-4-7 EDN: YCSVFZ
  16. James C, Bernstein DI. Allergen immunotherapy: an updated review of safety. Curr Opin Allergy Clin Immunol. 2017;17(1):55–59. doi: 10.1097/ACI.0000000000000335
  17. Kusić N, Plavšić A, Đurić V, et al. Systemic allergic reactions to subcutaneous allergen immunotherapy-a single-center experience. Life (Basel). 2025;1510:1527. doi: 10.3390/life15101527 EDN: KNGWRS
  18. Dhamija Y, Epstein TEG, Bernstein DI. Systemic allergic reactions and anaphylaxis associated with allergen immunotherapy. Immunol Allergy Clin North Am. 2022;42(1):105–119. doi: 10.1016/j.iac.2021.09.001 EDN: MEEIDS
  19. Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;73(4):765–798. doi: 10.1111/all.13317 EDN: YEXAHJ
  20. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(Suppl 1):S1–S55. doi: 10.1016/j.jaci.2010.09.034

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © ABV-press, 2026

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-42773 от  21.07.2009.